dihexa plasma half life Figure 1 from The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate Terminal half-life and the time

This extended period of efficacy stems from Dihexa's ability to modulate the expression levels of synapse-associated proteins (such as PSD-95, GluA1, etc.), rather than simply stimulating neuronal electrical activity

Novo Nordisk frames the therapy as a potential first-in-class diabetes option and intends to discuss a regulatory pathway with authorities

Sandforth, A

In large doses, it can cause excessive body stimulation, restlessness, insomnia, increased blood pressure, nervousness, inability to concentrate, headaches, and nosebleeds [218,219]

Yet, up to one third of community-dwelling older adults that display significant AD-like neuropathology post-mortem experience negligible reported cognitive decline in life 2,3